newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

  • IGC Pharma will demonstrate its Agentic Harmonization Assistant (AHA) AI platform at the Alzheimer's & Parkinson's Diseases Conference (ADPD) 2026.
  • The demonstration occurs in collaboration with the Alzheimer's Disease Data Initiative (ADDI), a global data-sharing platform supported by Gates Ventures.
  • AHA is an agent-based AI system designed to automate the harmonization of fragmented biomedical datasets, including clinical trial data and imaging.
  • The platform aims to replace time-consuming manual data preparation, significantly reducing the time required to analyze large datasets.
  • CEO Ram Mukunda stated that AHA supports the analysis of complex clinical data for lead candidate IGC-AD1, currently in the Phase 2 CALMA trial for agitation in Alzheimer's disease.
  • IGC Pharma views scalable data harmonization as a potential future revenue source to support pharmaceutical companies and global research collaborations.
  • The company's pipeline includes IGC-AD1, TGR-63 (targeting amyloid plaques), and early-stage programs focused on tau proteins and metabolic dysfunctions.
  • Forward-looking statements in the release cite risks including regulatory approval for cannabis-based products, AI algorithm performance, and general economic conditions.